特发性肺纤维化的治疗进展
Therapeutic advances in idiopathic pulmonary fibrosis.
摘要(中文译文)
特发性肺纤维化（IPF）以肺内瘢痕组织进行性积聚为特征，中位预期生存期为2～4年。直到最近，治疗选择仍然有限，主要集中在无效的抗炎治疗、姑息治疗、移植或临床试验招募。该领域近期取得的重大进展带来了两种新型抗纤维化药物——吡非尼酮和尼达尼布，已被证明可显著延缓IPF的疾病进展。本文概述了IPF的管理方法、专科中心的作用以及间质性肺病专科多学科讨论，并探讨了这些抗纤维化药物的试验证据和实际应用中的考量。
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive accumulation of scar tissue in the lung and is associated with a median life expectancy of 2-4 years. Until recently, treatment options were limited, focusing on ineffective anti-inflammatory therapy, palliation, transplant or trial recruitment. Significant recent advances in the field have led to two novel anti-fibrotic agents, pirfenidone and nintedanib, which have been shown to significantly slow disease progression in IPF. This article outlines the approach to management of IPF, the role of specialist centres and specialist interstitial lung disease multidisciplinary review, and explores both the trial evidence and practical considerations in the use of these anti-fibrotic agents.
如何引用
AMA
Emily Fraser, Rachel K Hoyles. Therapeutic advances in idiopathic pulmonary fibrosis.. Clinical medicine (London, England). 2016; doi:10.7861/clinmedicine.16-1-42.
APA
Emily Fraser, Rachel K Hoyles (2016). Therapeutic advances in idiopathic pulmonary fibrosis.. Clinical medicine (London, England). https://doi.org/10.7861/clinmedicine.16-1-42
GB/T 7714
Emily Fraser, Rachel K Hoyles. Therapeutic advances in idiopathic pulmonary fibrosis.[J]. Clinical medicine (London, England), 2016 doi:10.7861/clinmedicine.16-1-42.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出